These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

125 related articles for article (PubMed ID: 23919708)

  • 1. Primary prevention of cardiovascular disease: new guidelines, technologies and therapies.
    Nelson MR; Doust JA
    Med J Aust; 2013 Jun; 198(11):606-10. PubMed ID: 23919708
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Absolute cardiovascular disease risk and lipid-lowering therapy among Aboriginal and Torres Strait Islander Australians.
    Calabria B; Korda RJ; Lovett RW; Fernando P; Martin T; Malamoo L; Welsh J; Banks E
    Med J Aust; 2018 Jun; 209(1):35-41. PubMed ID: 29929455
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Absolute risk of cardiovascular disease events, and blood pressure- and lipid-lowering therapy in Australia.
    Banks E; Crouch SR; Korda RJ; Stavreski B; Page K; Thurber KA; Grenfell R
    Med J Aust; 2016 May; 204(8):320. PubMed ID: 27125809
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Under-use of appropriate blood pressure-lowering and lipid-lowering therapy in the Busselton baby boomer population.
    Yiu W; Knuiman M; Wallace H; Hung J
    Aust J Gen Pract; 2019 Dec; 48(12):883-889. PubMed ID: 31774993
    [TBL] [Abstract][Full Text] [Related]  

  • 5. How do the Australian guidelines for lipid-lowering drugs perform in practice? Cardiovascular disease risk in the AusDiab Study, 1999-2000.
    Chen L; Rogers SL; Colagiuri S; Cadilhac DA; Mathew TH; Boyden AN; Peeters A; Magliano DJ; Shaw JE; Zimmet PZ; Tonkin AM;
    Med J Aust; 2008 Sep; 189(6):319-22. PubMed ID: 18803535
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Aspirin for primary prevention: yes or no?
    Selak V; Elley CR; Wells S; Rodgers A; Sharpe N
    J Prim Health Care; 2010 Jun; 2(2):92-9. PubMed ID: 20690297
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Hemostatic factors in Australian Aboriginal and Torres Strait Islander populations.
    Wang Z; Rowley K; Best J; McDermott R; Taylor M; O'Dea K
    Metabolism; 2007 May; 56(5):629-35. PubMed ID: 17445537
    [TBL] [Abstract][Full Text] [Related]  

  • 8. 'Work it out': evaluation of a chronic condition self-management program for urban Aboriginal and Torres Strait Islander people, with or at risk of cardiovascular disease.
    Mills K; Gatton ML; Mahoney R; Nelson A
    BMC Health Serv Res; 2017 Sep; 17(1):680. PubMed ID: 28950874
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effectiveness of blood pressure-lowering drug treatment by levels of absolute risk: post hoc analysis of the Australian National Blood Pressure Study.
    Ho CLB; Breslin M; Doust J; Reid CM; Nelson MR
    BMJ Open; 2018 Mar; 8(3):e017723. PubMed ID: 29555790
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Legacy Effect of Delayed Blood Pressure-Lowering Pharmacotherapy in Middle-Aged Individuals Stratified by Absolute Cardiovascular Disease Risk: Protocol for a Systematic Review.
    Ho CLB; Sanders S; Doust J; Breslin M; Reid CM; Nelson MR
    JMIR Res Protoc; 2017 Sep; 6(9):e177. PubMed ID: 28864428
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Landmark lipid-lowering trials in the primary prevention of cardiovascular disease.
    Chrispin J; Martin SS; Hasan RK; Joshi PH; Minder CM; McEvoy JW; Kohli P; Johnson AE; Wang L; Blaha MJ; Blumenthal RS
    Clin Cardiol; 2013 Sep; 36(9):516-23. PubMed ID: 23722477
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Drug prescription rates in secondary cardiovascular prevention in old age: Do vulnerability and severity of the history of cardiovascular disease matter?
    van Peet PG; Gussekloo J; den Elzen WP; Blom JW; de Waal MW; de Ruijter W
    Scand J Prim Health Care; 2015; 33(4):260-8. PubMed ID: 26683286
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Using Classification and Regression Trees (CART) to Identify Prescribing Thresholds for Cardiovascular Disease.
    Schilling C; Mortimer D; Dalziel K; Heeley E; Chalmers J; Clarke P
    Pharmacoeconomics; 2016 Feb; 34(2):195-205. PubMed ID: 26578402
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Implications of the New National Guidelines for Hypertension.
    Aronow WS; Frishman WH
    Cardiol Rev; 2018; 26(2):55-61. PubMed ID: 29419560
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Essential service standards for equitable national cardiovascular care for Aboriginal and Torres Strait Islander people.
    Brown A; O'Shea RL; Mott K; McBride KF; Lawson T; Jennings GL;
    Heart Lung Circ; 2015 Feb; 24(2):126-41. PubMed ID: 25459487
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prioritising CVD prevention therapy - absolute risk versus individual risk factors.
    Doust J; Sanders S; Shaw J; Glasziou P
    Aust Fam Physician; 2012 Oct; 41(10):805-9. PubMed ID: 23210106
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Underutilisation of cardiovascular medications among at-risk individuals.
    Lewis SJ; Robinson JG; Fox KM; Grandy S;
    Int J Clin Pract; 2010 Apr; 64(5):604-10. PubMed ID: 19909379
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effect of a computer-guided, quality improvement program for cardiovascular disease risk management in primary health care: the treatment of cardiovascular risk using electronic decision support cluster-randomized trial.
    Peiris D; Usherwood T; Panaretto K; Harris M; Hunt J; Redfern J; Zwar N; Colagiuri S; Hayman N; Lo S; Patel B; Lyford M; MacMahon S; Neal B; Sullivan D; Cass A; Jackson R; Patel A
    Circ Cardiovasc Qual Outcomes; 2015 Jan; 8(1):87-95. PubMed ID: 25587090
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Association of Blood Pressure Lowering With Mortality and Cardiovascular Disease Across Blood Pressure Levels: A Systematic Review and Meta-analysis.
    Brunström M; Carlberg B
    JAMA Intern Med; 2018 Jan; 178(1):28-36. PubMed ID: 29131895
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [2013 Ambulatory blood pressure monitoring recommendations for the diagnosis of adult hypertension, assessment of cardiovascular and other hypertension-associated risk, and attainment of therapeutic goals (summary). Joint recommendations from the International Society for Chronobiology (ISC), American Association of Medical Chronobiology and Chronotherapeutics (AAMCC), Spanish Society of Applied Chronobiology, Chronotherapy, and Vascular Risk (SECAC), Spanish Society of Atherosclerosis (SEA), and Romanian Society of Internal Medicine (RSIM)].
    Hermida RC; Smolensky MH; Ayala DE; Portaluppi F; Crespo JJ; Fabbian F; Haus E; Manfredini R; Mojón A; Moyá A; Piñeiro L; Ríos MT; Otero A; Balan H; Fernández JR
    Clin Investig Arterioscler; 2013; 25(2):74-82. PubMed ID: 23849214
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.